Cycle Group to Acquire Applied Therapeutics in Private Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: NASDAQ.COM
Acquisition Details: Applied Therapeutics Inc. has agreed to be acquired by Cycle Group Holdings Ltd., with a tender offer of $0.088 per share in cash and additional contingent value rights tied to future regulatory milestones for their lead candidate, Govorestat.
Govorestat's Potential: Govorestat is being developed for treating rare CNS metabolic diseases, including Classic Galactosemia and CMT-SORD, with potential cash payouts for shareholders upon FDA approvals and sales milestones.
Financial Support: Applied Therapeutics has issued an $8.5 million unsecured promissory note to Cycle to support operations until the acquisition closes, as they indicated they could not continue operations without this funding.
Market Performance: APLT's stock has seen significant declines, trading between $0.20 and $1.50, closing at $0.21 before dropping to $0.14 in overnight trading, reflecting a 34.53% decrease.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on APLT
Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 0.25 USD with a low forecast of 0.25 USD and a high forecast of 0.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 0.093
Low
0.25
Averages
0.25
High
0.25
Current: 0.093
Low
0.25
Averages
0.25
High
0.25
About APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
Continue Reading
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
Continue Reading